Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 1,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 1,000 shares of Natera stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $89.55, for a total value of $89,550.00. Following the completion of the sale, the insider now directly owns 69,082 shares in the company, valued at $6,186,293.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total transaction of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34.
• On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $90,834.08.
• On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The shares were sold at an average price of $70.00, for a total transaction of $420,000.00.

Natera Price Performance

Shares of NTRA opened at $91.66 on Friday. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The stock has a 50 day moving average price of $87.72 and a 200 day moving average price of $67.16. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $98.82.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Equities analysts predict that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. Craig Hallum initiated coverage on Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target for the company. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their price target for the company from $68.00 to $85.00 in a research report on Tuesday, February 20th. Piper Sandler raised their price objective on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Finally, Stephens reiterated an “overweight” rating and issued a $78.00 target price on shares of Natera in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Institutional Trading of Natera

Large investors have recently bought and sold shares of the business. RiverPark Advisors LLC purchased a new position in shares of Natera during the fourth quarter worth about $27,000. Principal Securities Inc. purchased a new stake in shares of Natera during the fourth quarter worth approximately $32,000. YHB Investment Advisors Inc. acquired a new stake in shares of Natera in the 1st quarter worth $36,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the third quarter valued at about $44,000. Finally, Oliver Lagore Vanvalin Investment Group increased its stake in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.